de Godoy Journal of Medical Case Reports 2010, 4:295 http://www.jmedicalcasereports.com/content/4/1/295 together with reddish spots was confirmed, predomi- nantly on the distal third of his legs including his ankle region. He did not suffer from varicose veins or telan- giectasias. The clinical diagnosis was stasis purpura and he was medicated with 75 mg aminaphtone, twice daily until the lesions disappeared completely, which took about 11 months. No new lesions appeared during a three-year follow-up period. Case 3 A 51-year-old Caucasian man presented with a history of brown spots on his lower leg. These had appeared as reddish spots approximately two years previously and became brown over time. On physical examination, brown patches together with reddish punctiform pete- chiae were found on the lower third of his leg up to the ankle region. CEAP C1 telangiectasia was observed in both of his legs. A clinical diagnosis of stasis purpura was made and he was medicated with 75 mg aminaph- tone, twice daily until the lesions disappeared, which took about 13 months. No new lesions appeared during a one-year follow-up period. Case 4 A 56-year-old Caucasian woman presented with pain in her legs, progressive brown patches and varicose veins over a period of four years. On physical examination, dilated veins, edema, brownish patches and reddish punctiform spots were observed, involving the lower third of her limbs and ankle regions. A Doppler echo- gram was performed that demonstrated saphenous vein insufficiency and collateral varicose veins. She was sub- mitted to varicose vein surgery for resection of her saphenous vein and collateral varicose veins. A clinical diagnosis of stasis purpura was made and she was pre- scribed 75 mg aminaphtone until the brown patches disappeared, which took about 14 months. No new lesions have appeared over the last two years. Discussion I describe the clinical improvement of stasis purpura with aminaphtone. Aminaphtone is a common name for compound 2-hydroxy-3-methyl-1,4-napthohydroqui- none-2-p-aminobenzoate. To the best of my knowledge, this approach has not been described in the literature and thus this is a novel therapeutic option. One hypothesis is that a possible cause of stasis pur- pura is capillary fragility and by improving this fragility it is possible to treat and even eliminate this form of purpura. Initially, the appearance of new punctiform spots is controlled and then there is a gradual reduction in the size of the brown patches. An important aspect of therapy is the duration of treatment. This has proven to be about one year, after Page 2 of 3 which time a total elimination of the brown patches is evidenced. All patients were followed up every two months, when control of the appearance of new lesions and a reduction of existing lesions was observed. It is important that patients are made aware of the expected duration of the treatment as they will want to see immediate results. Photographic documentation is recommended for clinical evolution control purposes. The use of aminaphtone for short periods, such as one month, does not seem to be efficacious, and so the duration of treatment is the determining factor. The only side effect reported by a minority of the patients was gastric irritation. The lack of efficacious therapeutic alternatives with respect to this disease drew my attention. Additionally, younger patients (20 to 30 years old), without evidence of clinical varicose veins (CEAP 0 and 1) are affected. This suggests that capillary fragility plays an important role in the development of this type of lesion. Even so, patients with more advanced chronic venous insuffi- ciency (CEAP 5 and 6) can present with lesions and might benefit from this treatment. This treatment inter- feres in the physiopathology of the disease. Stasis der- matitis has been observed in some CEAP 4, 5 and 6 patients, frequently involving the entire circumference of the lower third of the leg, including regions unaf- fected by venous backflow. This observation suggests changes in capillary permeability. After a few days of treatment, new reddish petechiae did not appear suggesting that the capillary fragility was controlled. The decision to maintain treatment over a prolonged period was reached due to the lack of infor- mation about how long this drug maintains control of capillary fragility and to evaluate the final result. This case report presents the results of four randomly-chosen patients in order to illustrate the approach; however, more than 40 patients have been treated and followed up in this period and all had similar results. Currently, I prescribe aminaphtone daily for a period of two months and then in alternate weeks. There is a necessity to establish the best treatment regimen to determine for how long aminaphtone is necessary. Some patients have attained control without the appearance of petechiae for more than three years after the cessation of the drug, suggesting long-term control. The use of aminaphtone to control nose bleeds has been observed for more than three years after the suspension of the drug in the cases of patients that had been restricted from participating in social activities due to the bleeding [5]. This suggests that after the initial control of capillary fragility, long- term or definitive maintenance is obtained. Aminaph- tone has also been utilized in the control of idiopathic cyclic edema [6].